Side effects of CJC-1295 and Ipamorelin – complete safety guide

CJC-1295 and ipamorelin have generally shown a low incidence of serious adverse events in the small, short-term clinical trials conducted to date. However, neither compound has been studied long enough or broadly enough in humans to speak with certainty about their full safety. Several commonly discussed side effects – like skin flushing or water retention – are also not well-documented in the controlled studies reviewed for this article. This guide separates what has actually been reported in clinical studies from what remains anecdotal or theoretical – which is critically important when evaluating safety claims about unapproved compounds.

What are the side effects of CJC-1295?

The most direct clinical safety data for CJC-1295 come from the initial human study, which included two randomized, double-blind, placebo-controlled trials in healthy adults. This study specifically noted that no serious adverse reactions occurred, with researchers considering doses of 30 or 60 micrograms per kilogram of body weight to be safe and relatively well tolerated [1]. However, it is worth noting that the statement „no serious adverse reactions” is quite general, and the originally published study does not provide a detailed, itemized breakdown of every minor side effect experienced by the participants—which limits how precisely this article can describe the full picture of symptoms.

A 2026 review examining performance-enhancing peptides acting on the growth hormone–IGF-1 axis, encompassing both DAC-present and DAC-absent CJC-1295 alongside ipamorelin, described a broader set of adverse effects reported within this class of compounds in both clinical and self-administration contexts. These included endocrine and metabolic disturbances, such as elevated prolactin and cortisol, changes in appetite, and dysglycemia (impaired blood glucose regulation), as well as fluid retention, musculoskeletal symptoms like muscle or joint pain, and injection site reactions [2].

It is important to note that this review broadly encompassed the entire category of growth hormone secretagogues and GHRH analogs, drawing on both peer-reviewed pharmacokinetic evidence and observed patterns in real-world self-administration, rather than reporting on a controlled number of side effects specific solely to CJC-1295. These findings should therefore be understood as representative of the entire class of compounds, rather than a confirmed, itemized side effect profile for CJC-1295.

Why do CJC-1295 and ipamorelin cause skin flushing?

Skin redness, water retention, and numbness or tingling are frequently mentioned in informal user accounts or reports. However, controlled clinical trials reviewed for this article do not specifically document redness as a measured or reported side effect of CJC-1295 or ipamorelin, so a confirmed physiological explanation for redness cannot be provided based on this body of evidence. Fluid retention, it can be said, has been described as one of the adverse effects associated with growth hormone axis-modulating peptides more broadly, including CJC-1295 and ipamorelin, in the review discussed above. This is generally consistent with well-established general endocrinology, where growth hormone and IGF-1 are known to affect fluid balance within the body [2]. However, this article cannot definitively state that redness specifically has a confirmed mechanism linked to CJC-1295 or ipamorelin, as this particular symptom was not identified as a documented finding in the peer-reviewed sources reviewed.

Injection site reactions – such as redness, irritation, or discomfort at the injection site – are mentioned in the same broader safety review of peptides as a recognized adverse effect in this class of compounds. This is a likely and common occurrence with essentially any subcutaneously administered peptide, although again, this reflects a general finding across the drug category rather than a controlled measurement specific to CJC-1295 [2]. Given these gaps, any specific claims about exactly why or how often redness, numbness, or tingling occurs with CJC-1295 or ipamorelin should be considered anecdotal rather than clinically established.

Are CJC-1295 and ipamorelin safe?

Neither CJC-1295 nor ipamorelin can be accurately described as „safe” or „dangerous” in an absolute sense. The honest answer is that short-term data from small, controlled study populations appear reassuring, while long-term safety with general, unsupervised use remains truly unknown. For ipamorelin, one of the more informative safety datasets comes from a randomized, placebo-controlled Phase 2 clinical trial in patients undergoing bowel resection. Ipamorelin was administered as an intravenous infusion twice daily for up to seven days under close medical supervision. In this study, the overall incidence of any treatment-related adverse event was 87.5% in the ipamorelin group, compared to 94.8% in the placebo group—meaning that adverse events were no more frequent with ipamorelin than with placebo in this specific surgical population [3].

This is an important data point, but it comes from a hospitalized, closely monitored surgical population receiving a specific low IV dose for a specific medical purpose. It does not necessarily reflect what would happen with self-administration subcutaneously for weeks or months in a healthy, non-hospitalized person seeking muscle growth or anti-aging effects.

For CJC-1295, safety data are similarly reassuring, yet similarly limited in scope, relying on short study periods of 28–49 days in healthy volunteers under clinical supervision [1]. Many recent scientific reviews covering this entire category of growth hormone axis peptides have clearly highlighted this gap, stating that rigorous human safety data remain sparse for many of these unapproved compounds, and that there is a real potential for harm when they are used outside of monitored clinical settings – particularly given the inconsistent product quality in the unregulated peptide supply chain [4], [5]. In short, the available short-term evidence has not shown alarming safety signals. However, „not shown to be dangerous in a small, short study” is a very different statement from „proven safe with long-term use,” and current evidence does not support the latter claim.

Allergic reaction to CJC-1295 and ipamorelin

No published clinical trials reviewed for this article have specifically documented allergic or hypersensitivity reactions to CJC-1295 or ipamorelin. This means it remains an area without direct evidence, rather than one that can be confidently described as low or high risk. As a general rule of peptide pharmacology, any injected peptide – including growth hormone secretagogues such as these – carries a theoretical possibility of eliciting an immune or allergic response in an individual, as peptides can fundamentally be recognized by the immune system as foreign material. However, this is a general pharmacological consideration and not a documented finding specific to CJC-1295 or ipamorelin.

Since dedicated data on hypersensitivity or contraindications for these specific compounds was not identified in the reviewed peer-reviewed literature, this paper cannot list specific allergy symptoms, risk factors, or contraindications with certainty. Doing so would risk presenting fabricated or unsupported information as fact.

What the evidence shows, and what remains unknown

Limitations of current evidence

The safety profile for CJC-1295 and ipamorelin is built almost entirely on short-term studies—weeks, not months or years—conducted on small, highly selected, and tightly monitored populations: healthy volunteers for CJC-1295 and hospitalized surgical patients for the most detailed adverse event data for ipamorelin.

None of these scenarios reflect how these compounds are typically used outside of clinical trials, and many recent reviews explicitly acknowledge that long-term human safety data simply does not yet exist for this peptide category [4, 5]. Common anecdotal side effects like skin redness, water retention, and injection site numbness frequently arise in informal or commercial discussions about these compounds. However, this article found limited to no direct support for several of these specific claims in the peer-reviewed literature, which is a significant distinction between what is scientifically documented and what circulates anecdotally.

Disclaimer

This content is for educational purposes only and does not constitute medical advice, diagnosis, or therapeutic recommendation. CJC-1295 and Ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. The safety information presented here reflects findings from short-term clinical trials in small, closely monitored populations and does not constitute confirmed long-term safety data.

References

Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

[2] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475

Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8

Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. Advance online publication. https://doi.org/10.1007/s40279-026-02437-0

[5] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1